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Abstract 
 
Fatty acid oxidation inhibition is one approach to reducing blood glucose levels in type II 
diabetes. Skeletal muscle specific Carnitine Palmitoyltransferase 1b knockout mice (Cpt1bm-/-) 
cannot transport long-chain fatty acids into the mitochondria to be oxidized in order to produce 
energy. Cpt1bm-/- mice have debilitated fat oxidation, less fat mass and improved glucose 
utilization compared to control C57BL/6 mice fed a 25% fat diet.  
We hypothesized that CPT1b inhibition could reduce fat mass and lower blood glucose 
levels in a genetic mouse model of obesity and diabetes. To test this, we bred Cpt1bm-/- mice to 
AY mice. AY mice, also referred to as lethal yellow mice, are mutated at the mouse agouti locus 
causing a yellow coat. AY mice are prone to obesity, diabetes, tumors and cancers. The goal of 
this study was to determine the effect of extended inhibition of fatty acid transport into skeletal 
muscle mitochondria in AY: Cpt1bm-/- mice. 
Compared to AY mice, AY: Cpt1bm-/- mice were more insulin sensitive and glucose 
tolerant. AY: Cpt1bm-/- mice showed improved performance on glucose and insulin tolerance tests 
despite minimal differences in fat mass between groups. However, liver weights of AY: Cpt1bm-/- 
mice were significantly less than liver weights of AY mice. 
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Introduction 
 
1.1. Modern Treatment Plans for Obesity and Type 2 Diabetes 
 
Current treatment plans for obesity and type 2 diabetes include lifestyle-intervention 
programs or administration of metformin. Both treatments have been shown to reduce the 
incidence of diabetes in high risk individuals (Knowler, 2002). Thiazolidinediones (TZDs) drugs 
serve as insulin sensitizers through decreasing the production and increasing the disposal of 
glucose. TZD has been shown to activate AMPK and increase mitochondrial biogenesis in 
adipose tissue (Wilson-Fritch et al., 2004).  Mitochondrial inhibition in skeletal muscle also 
improves insulin sensitivity (Pagel-Langenickel, Bao, Pang, & Sack, 2010). Investigation of 
diabetic and obesogenic mouse models aids in the development of new treatment plans for the 
prevention and amelioration of obesity and type 2 diabetes.  
 
1.2. History of AY Mice 
 
Lethal yellow (AY) mutated mice are a genetically obese and diabetic mouse model 
commonly used for the study of obesity and insulin resistance. AY mice have a mutation on 
chromosome 2 at the agouti locus. All surviving mice with the AY mutation are heterozygous for 
the AY mutation. Mice that are homozygous for the AY mutation will result in embryonic 
lethality before implantation (Iwatsuka, Shino, & Suzuoki, 1970). This mutation causes these 
mice to overexpress agouti which results in a completely yellow coat color and a genetically 
obese and diabetic mouse model. AY mice are prone to yellow obese syndrome which consists of 
obesity, hyperglycemia, hyperinsulinemia, increased tumor incidence and increased skeletal and 
muscle growth (Miltenberger, Mynatt, Wilkinson, & Woychik, 1997). It is common for AY mice 
to become infertile a few months after birth (Iwatsuka et al., 1970). In a preferential 
macronutrient study, AY mice consumed higher amounts of fat than carbohydrate and protein. 
This preference for fat could explain their increase in overall body fat content. Antagonists to the 
melanocortin receptors (MC-Rs) or increased palatability could be credited for the preferential 
consumption of fat in these mice. Liver weights for AY mice, expressed as absolute weight or as 
percent of body weight, were both found to be significantly heavier relative to control mice. 
(Koegler, Schafffhauser, Mynatt, York, & Bary, 1999) 
  The agouti gene locus manages the distribution of eumelanin (brown and black) and 
pheomelanin (red and yellow) for coat pigmentation. Agouti is a small protein made up of 131 
amino acids (Wang & Majzoub, 2011). Agouti antagonizes α-melanocyte-stimulating hormone 
(α-MSH) by blocking the actions of follicular melanocytes at the melanocortin 1 receptor 
(MC1R). MC1R is a highly expressed G protein-coupled receptor found in melanocytes. 
Melanocytes are cells responsible for pigment production. Under normal circumstances, α-MSH 
would activate MC1R which would elevate cAMP levels and increase the production of 
eumelanin. If agouti is present, it serves as an antagonist to MC1R which results in decreased 
eumelanin and increased pheomelanin production (Nachman, Hoekstra, & D'Agostino, 2003). 
This is what causes the phenotypic yellow coat color observed in heterozygous AY mice. Agouti  
can also serve as an antagonist to neural melanocortin receptors, MC4R and MC3R; however, 
the interaction with MC3R is notably weaker (Wang & Majzoub, 2011). The melanocortin 
system only has two known antagonists, agouti related protein (AGRP) and agouti (Tao, 2010). 
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The paracrine signaling molecule known as agouti related protein (AGRP) is known to 
regulate body weight. It serves as an antagonist to both neural melanocortin receptors, MC3R 
and MC4R (Ollmann, 1998). It is expressed at highest amounts in the hypothalamus and adrenal 
medulla. Lower levels of expression can be seen in the testis, lung and kidney (Wang & 
Majzoub, 2011). Normally, leptin is released from adipose tissue and it acts upon melanocortin 
neurons or AGRP neurons. This results in increased α-MSH and decreased AGRP. When α-
MSH binds MC4R, it inhibits food intake and increases energy expenditure. If AGRP blocks α-
MSH, food intake is increased and energy expenditure decreases (Dutia et al., 2013). At the 
melanocortin receptor in the skin, MC1R, agouti blocks α-MSH from binding which results in a 
yellow coat color. Since agouti can also antagonize MC4R and MC3R, it also has the ability to 
block neural α-MSH. Therefore, a ubiquitous promoter driving the overexpression of agouti 
results in a yellow coat color when the α-MSH in the skin is blocked by agouti as well as obesity 
when the α-MSH in the brain is blocked by agouti. The phenotype associated with the 
heterozygous lethal yellow (Ay) mutated mice can be explained by the overexpression of agouti; 
however, the embryonic lethality found in mice that are homozygous for this mutation is caused 
by the deletion of another gene.   
The AY mutation is brought about by a 170 kb excision which removes a gene known as 
Raly which is positioned upstream of the agouti locus. The Raly gene promoter and first 
noncoding exon is all that remains after the deletion (Michaud et al., 1994). Essentially, what 
happens is Raly’s promoter splices into the open reading frame of the agouti gene and begins to 
drive the expression of agouti which results in ubiquitous overexpression of agouti. The excision 
of the Raly gene is believed to be the cause of lethality in mice that are homozygous for this 
mutation (Michaud et al., 1994). The genetically induced obesity and insulin resistance found in 
these mice makes for a desirable model for obesogenic and diabetic research.   
 
1.3. The Skeletal Muscle Specific Cpt1bm-/- Knock Out Mice 
 
The enzyme Cpt1 resides in the outer mitochondrial membrane and is responsible for 
catalyzing the reaction necessary for the transport of long chain fatty acids into the inner 
mitochondrial membrane where beta oxidation can occur. The Cpt1 isoform of interest is Cpt1b 
since this is the form found in skeletal muscle. Cpt1b is one of three isoforms with the other two 
being Cpt1a and Cpt1c. Cpt1a is expressed ubiquitously with exceptions being skeletal muscle 
and brown adipose tissue. Its largest expression is found in the liver. Cpt1b is expressed in heart, 
skeletal muscle and brown adipose tissue and Cpt1c can be found in the brain and testes (Rufer, 
Thoma, & Hennig, 2009). When Cpt1b is knocked out in skeletal muscle, long chain fatty acyl-
CoAs cannot be conjugated to L-carnitine. Since acyl-CoA cannot cross into the mitochondrial 
matrix through simple diffusion, fatty acid beta oxidation is inhibited in skeletal muscle (Cobb & 
Dukes, 1998). 
Through the use of transgenes and mouse genome manipulation, knock out mouse 
models are designed to allow for a deeper understanding of diabetes and obesity. The Cpt1b 
muscle specific knock out in this study was achieved by crossing mice with floxed alleles of 
Cpt1b to Mlc1f-Cre transgenic mice for skeletal muscle specific deletion of Cpt1b, but not 
cardiac tissue (Shawna E. Wicks et al., 2015). Previous studies using this mouse model noted 
that despite ectopic lipid accumulation in muscle, Cpt1b-/- mice maintained insulin sensitivity 
while on a moderate fat (25% kcal) breeder chow diet (S. E. Wicks et al., 2015). Additionally, 
skeletal muscle specific Cptlbm-/- mice had improved glucose uptake along with induced Fgf21 
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expression in muscle. A double knockout mouse model of Cpt1b and Fgf21 showed a partial 
negation in improved glucose utilization in comparison to Cpt1b knock outs. Fgf21 appeared to 
be partially responsible for the increase in glucose utilization in a manner that was independent 
of the stress signaling pathway but dependent on AMPK and Akt1 signaling (Vandanmagsar et 
al., 2016).   
 
1.4. Controversial Research Regarding Inhibition and Upregulation of B-Oxidation in 
Skeletal Muscle  
 
Whether overexpression or inhibition of Cpt1 in skeletal muscle is needed to improve 
insulin resistance is a controversial topic with literature supporting both concepts. Cpt1 
overexpression in skeletal muscle was found to be sufficient for mitigating lipid-induced insulin 
resistance in a rat study. Overexpression was achieved through in vivo electro transfer of a 
purified Cpt1 plasmid via direct injection into the tibialis anterior of rats. Extensor digitorum 
longus (EDL) was the muscle used for measuring glucose uptake due to its close proximity with 
the tibialis anterior. Overexpression of Cpt1 in the EDL of rats fed high fat diet for a 4-week 
period enhanced insulin stimulated glucose uptake to similar levels seen in the control rats fed a 
chow diet (Bruce et al., 2009). Similar results were found in a study where increased B-oxidation 
in muscle cells was enough to increase glucose metabolism stimulated by insulin and protect 
against fatty acid induced insulin resistance. B-oxidation in myocytes was enhanced by 
transducing myotubules with an adenovirus encoding Cpt1. They proposed that enhanced B-
oxidation in muscle was enough to exert an insulin sensitizing effect despite no change in 
intramyocellular lipid accumulation (Perdomo et al., 2004). A study using myotubules found 
overexpression of Cpt1 protected against fatty acid induced insulin resistance. This 
overexpression lead to a reduction in the accumulation of lipid in muscle tissue thus diminishing 
the likelihood of fulfilling the lipotoxic model of skeletal muscle insulin resistance hypothesis 
(Sebastian, Herrero, Serra, Asins, & Hegardt, 2007).  
Contrary to the findings above, another study found deficiency in Cpt1b protected mice 
from diet induced obesity. The animals in this study had a global heterozygous Cpt1b+/- knockout 
and therefore showed that partial inhibition of Cpt1b was sufficient to protect from insulin 
resistance when fed a high fat diet for up to 5 months (Kim, He, et al., 2014). A later study found 
the partial knock out mice developed severe insulin resistance after 7 months on the high fat diet, 
providing further justification for our homozygous knock out model (Kim, Moore, et al., 2014). 
Oxfenicine, a Cpt1 inhibitor, was used to hinder Cpt1 activity consequently alleviating insulin 
resistance associated with diet induced obesity. Findings included increased carbohydrate 
utilization and improvement in insulin signaling in skeletal muscle, proposing a possible Randle 
Cycle in skeletal muscle (Keung et al., 2013). Malonyl-CoA decarboxylase (mcd-/-) knockout 
mice were generated to inhibit fat catabolism in skeletal muscle. Malonyl-CoA decarboxylase 
(MCD) is the enzyme that converts malonyl CoA to acetyl CoA and CO2. In doing so, MCD 
prevents the buildup of malonyl CoA, a known inhibitor of Cpt1. Therefore, when MCD is 
knocked out, malonyl CoA will build up and inhibit Cpt1 and thus fatty acid oxidation in skeletal 
muscle. Results from this study showed mcd-/- mice resisted diet induced glucose intolerance 
despite having higher than normal intramuscular levels of long-chain acyl-CoAs (Koves et al., 
2008).  
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1.5. Existing Theories for Skeletal Muscle Insulin Resistance 
 
This leads to discussion of two competing theories pertaining to skeletal muscle insulin 
resistance.  The first theory states that excess ectopic lipid buildup leads to insulin resistance 
because lipid overload interferes with insulin signaling. Hardy et al. says the accumulation of 
ectopic lipid in skeletal muscle may cause insulin resistance through the formation of toxic 
intermediates; for example, saturated fats have presented evidence of increased ceramide 
production, which seems to augment insulin resistance (Hardy, Czech, & Corvera, 2012). A 
buildup of diacylglycerols (DAGs) has been shown to activate isoforms of novel protein kinase 
C which leads to phosphorylation of insulin receptor substrate-1 (IRS-1), resulting in impaired 
downstream insulin signaling. The term “lipotoxicity” has been coined to define the state in 
which excess lipid accumulation leads to insulin resistance in skeletal muscle (Badin et al., 
2011).  
The contending theory states that excess ectopic lipids are partially broken down by 
mitochondria, and the incompletely broken-down intermediates are toxic, which then interfere 
with insulin signaling. A study found skeletal muscle insulin resistance to be indicative of 
elevated fatty acid catabolism rates which resulted in incomplete fatty acid B-oxidation and a 
large portion of fatty acids entering the mitochondria resulting in only partial degradation. 
Further characteristics of skeletal muscle insulin resistance from this study included debilitated 
switching of fuel substrates between the fed-to-fasted transition (“metabolic inflexibility”) and a 
deficiency in multiple Krebs cycle intermediates (Koves et al., 2008). Additionally, inhibition of 
fatty acid transport into the mitochondria of skeletal muscle resulted in a rather remarkable 
phenotype where mice remained insulin sensitive despite ectopic lipid accumulation in the 
muscle (S. E. Wicks et al., 2015).  
Since Cpt1b skeletal muscle specific knockout mouse models have been shown to have 
ectopic lipids yet no insulin resistance, we favor the latter theory. Without Cpt1b the 
mitochondria are not capable of breaking down fatty acids; therefore, the culprit for insulin 
sensitivity interference may be the toxic incompletely broken-down intermediates rather than 
ectopic lipid buildup.  
Based off the data mentioned above regarding Cpt1 overexpression and insulin 
sensitivity, increased capacity for breaking down lipids may also prevent the buildup of toxic 
intermediates. However, some warn against the use of pharmacologic strategies geared toward 
boosting B-oxidation to alleviate muscle insulin resistance, suggesting fatty acids must penetrate 
muscle mitochondria in order to exert insulin-desensitizing effects. Their evidence proposes 
obesity-associated glucose intolerance arising from metabolic overload of muscle mitochondria 
which could potentially result from excessive B-oxidation (Koves et al., 2008). Another study 
found similar results against the use of excessive B-oxidation for ameliorating skeletal muscle 
insulin resistance. While studying gain-and-loss-of-function of peroxisome proliferator-activated 
receptor-α (PPAR-α) in regards to the development of insulin resistance, transgenic mice 
overexpressing PPAR-α in muscle resulted in increased rates of fatty acid oxidation along with 
glucose intolerance. PPAR-α null mice were protected from insulin resistance. Oxfenicine, an 
inhibitor of skeletal muscle Cpt1, was administered to the transgenic mice overexpressing 
PPAR-α, resulting in lipid accumulation in skeletal myocytes and improved glucose tolerance 
(Finck et al., 2005). Herein, we align with the hypothesis for protection from skeletal muscle 
insulin resistance with reduced rather than excessive fatty acid oxidation.  
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1.6. Combinational Approach in this Study 
 
The overall objective of this project is to determine if inhibiting skeletal muscle 
mitochondrial fatty acid oxidation can help improve insulin resistance and weight loss in a 
genetically obese and diabetic mouse model. The hypothesis made states that carnitine palmitoyl 
transferase (Cpt1b) inhibition specifically in skeletal muscle could improve fat mass and blood 
glucose levels in a genetic mouse model of obesity and diabetes. In an attempt to further 
understand how inhibiting fatty acid oxidation mediates insulin resistance and obesity, carnitine 
palmitoyltransferase (Cpt1b) was knocked out in skeletal muscle of a genetically obese mouse 
model known as lethal yellow (AY) mutated mice. Four genotypes were included: Control mice, 
Cpt1bm-/- mice, AY mice and AY: Cpt1bm-/- mice with focus throughout being primarily on AY: 
Cpt1bm-/- mice since the Cpt1bm-/- phenotype has been well established in prior studies (S. E. 
Wicks et al., 2015) (Vandanmagsar et al., 2016; Warfel et al., 2016). All mice from this study 
came from the C57BL/6 background.  
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Methods 
 
2.1. Animal Studies 
 
Animal studies took place at Pennington Biomedical Research Center’s American 
Association for the Accreditation of Laboratory Animal Care-approved facility, with mice 
receiving a standard chow diet, comprised of 25% fat, 55% carbohydrate and 20% protein 
(Mouse Chow Diet no. 5015; LabDiet). All procedures were in agreeance with the NIH Guide 
for the Care and Use of Laboratory Animals and authorized by the Institutional Animal Care and 
Use Committee. The majority of the mice used in this experiment were between the ages of 4 to 
8 months of age unless stated differently. 
 
2.2. Animal Procedures 
 
Body composition (fluid, fat mass, lean mass) was measured using a Bruker NMR 
Minispec (Bruker Corporation). Mice were weighed on a scale prior to each use of Minispec and 
bodyweights were recorded in grams. Serum and plasma collections were performed by 
submandibular bleed. Following a 4 hour fast, glucose tolerance tests (GTTs) were performed by 
intraperitoneal injection of 10% D-glucose (40 mg of glucose per mouse). Blood glucose was 
measured with a glucometer at 0, 20, 40 and 60 minutes via tail end snip. Insulin Tolerance tests 
(ITTs) were performed while in the fed state, using an intraperitoneal dose of 0.04 units (U) per 
mouse. Measurements were taken with a glucometer at 0, 20, 40 and 60 minutes via tail end snip. 
 
2.3. Metabolic Profiling 
 
ELISA kits were used for measurement of 4 hour fasted serum insulin (Ultra-Sensitive 
Mouse Insulin ELISA kit; Crystal Chem, Inc. #90080) and Triglycerides (TAGs) (Triglyceride-
H; Wako Diagnostics) and fed serum FGF21 (BioVendors). Liver TAGs were also measured 
(Triglyceride-H; Wako Diagnostics). Glycogen was measured in liver using a commercial kit 
(65620; Abcam) with instructions provided by the manufacturer.  
 
2.4. Hepatic Fluid Measurement 
 
Tissues were collected and patted free of exogenous blood prior to being snap frozen in 
liquid nitrogen. This procedure was precisely replicated for all livers collected. Aliquots ranging 
from 20-100 mg were collected from each whole liver for this dehydration experiments. Each 
aliquot was weighed before being placed in the NAPCO vacuum oven (model 5831). Samples 
were left in the vacuum overnight with the temperature control set at a 2.5 and vacuum at ≈ 5 
Hg. Desiccated samples were reweighed the next morning. The difference between the wet 
weight and desiccated weight was recorded for each sample and perceived as fluid level. Next, 
grams of fluid per grams of wet weight were determined by dividing the difference (fluid 
amount) for each sample by the weight of the aliquot prior to dehydration for each sample. Total 
fluid was determined by multiplying the value for grams of fluid per grams of wet weight for 
each sample with the original whole liver weight recorded at necropsy for each sample.   
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2.5. qRT-PCR 
 
Total RNA from mouse tissue (snap frozen on liquid nitrogen at the collection) was 
isolated using a RNeasy Mini Kit (Qiagen) and DNase was used to degrade DNA. cDNA 
synthesized with the iScript cDNA synthesis kit was used for qRT-PCR with the SYBR Green 
system (Bio-Rad). qRT-PCR was conducted using DDCT assay. Mouse cyclophilin B was used 
as the housekeeping-gene control for normalization of gene expression. Previously our lab 
demonstrated that all target and control genes showed appropriate amplification using standard 
curves. Primer details are provided in table 1.  
 
2.6. Histology 
 
Liver from mice were harvested and fixed with formalin. Then the tissues were 
embedded in paraffin and sectioned and stained with H&E at the Cell Biology and Bioimaging 
Core Facility at Pennington Biomedical Research Center. Images were viewed at a magnification 
of 5x using NDP.view2 software. 
 
2.7. Generation of Skeletal Muscle-Specific Cpt1b KO Mice 
 
Knock out mice were achieved through the use of the cre-lox system. This technology 
requires the generation of a cre-lox mouse via breeding. Typically, this is produced by mating a 
mouse positive for cre with a mouse with lox P sights flanking the gene of interest. Cre serves as 
a recombinase which is guided by a specific promoter which in this case is Mlc1f (Laboratory, 
2006). The Mlc1f-Cre transgene is used to ablate Cpt1b specifically in skeletal muscle but it 
remains highly expressed in cardiac tissue. This is because the Mlc1f promoter is specific for 
skeletal muscle. Mlc1f is one of two independent promoters located at the myosin light chain 
locus. These promoters are differentially activated during skeletal muscle development. The 
second promoter is known as Mlc3f. The Mlc1f promoter is used for skeletal muscle specific 
knock downs because the Mlc3f promoter has low level expression in the left atria and ventricle 
of mouse cardiac tissue (Kelly, Alonso, Tajbakhsh, Cossu, & Buckingham, 1995).  When the cre 
recombinase mouse is bred with the flanked lox P gene of interest mouse, cre will cut half of 
each lox P site resulting in the excision of the gene of interest from the genome and 
recombination of the remaining lox P halves. For this experiment, cre positive mice were bred to 
floxed Cpt1b mice in order to achieve a skeletal muscle specific Cpt1b knock out. Cpt1b muscle 
specific knock out mice were achieved by breeding Mlc1f-Cre recombinase mice (from Gerald 
Bothe, Wadsworth Center, Albany, NY) that were backcrossed for 10 generations to C57BL6 
mice; therefore, all mice are from the C57BL6 background. All chimeric mouse production and 
gene targeting was executed by the Transgenic Core at Pennington Biomedical Research Center.  
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Table 1. Primers and Sequences. This is a comprehensive list of forward and reverse primers 
used in this study.  
Gene Symbol Reference 
Sequencing ID 
Forward Primer Reverse Primer 
Hadha NM_178878 TGACGCTGGTTATCTTGCT
G 
ATCAGGGCCTTCGATTCTTT  
Ech1 NM_016772 TCGCTACTGCACTCAGGA
TG 
AGCAGCCAAGCCCATATCTA 
Bckdha NM_007533 GTGGGATGAGGAACAGGA
GA 
CTTGGGTTCGGCTTTAGCTT 
Bcat2 NM_001243052 CGCTTCCAGAAGGAACTG
AA 
CACACCCGAAACATCCAATC 
Cd36 NM_001159555 GCAAAGAACAGCAGCAA
AATC 
TCCTCGGGGTCCTGAGTTAT 
Fatp1 NM_011977 GGTGGTACTGCGCAAGAA
GT 
AGCGGCAGATTTCACCTATG 
Fabp3 NM_010174 GACGAGGTGACAGCAGAT
GA 
CTGCACATGGATGAGTTTGC 
Plin5 NM_001077348 CTTCCTGCCCATGACTGA
G 
ACCCCAGACGCACAAAGTAG 
Acox1  NM_015729 CTTCGAGGGGGAGAACAC
T 
CCCGACTGAACCTGGTCATA 
Fgf21 NM_020013 TTCTTTGCCAACAGCCAG
AT 
GTCCTCCAGCAGCAGTTCTC 
Cs NM_026444 CGGGAGGGCAGCAGTATC
GG 
ACCACCCTCATGGTCACTATGGA
TG 
Cyclophilin NM_011149 TCCATCGTGTCATCAAGG
ACTT 
CTCATCTGGGAAGCGCTCA 
Pdha1 NM_008810 GGTTGCTTCCCGTAATTTT
G 
GTGAGCACTGTGGTGACTGG 
Gdf15 NM_ 23886 GCTGTCCGGATACTCAGT
CC 
GTAGGCTTCGGGGAGACC 
Acaca NM_ 107476 ATGGTTGAGTGGGTTTTTT
GACTAT 
CCTAACCTGGCTCTGCCAACT 
Fasn NM_ 14104 GATCCTGGAACGAGAACA
CGAT 
TCGTGTCAGTAGCCGAGTCA 
Scd1 NM_ 20249 CCGGGAGAATATCCTGGT
TT 
TAGTCGAAGGGGAAGGTGTG 
Cpt1a NM_ 12894 CATGATTGCAAAGATCAA
TCGG 
CTTGACATGCGGCCAGTG 
Pck1 NM_ 18534 GGTGTCCCCCTTGTCTATG
AAG 
ATCTTGCCCTTGTGTTCTGCA  
 
  
9 
 
2.8. Generation of Skeletal Muscle-Specific Cpt1b KO and AY Mutated Mice 
 
The AY:Cpt1bm-/- mice are double mutated and may be referred to as Double Mutants 
(DMut Mice). The Cpt1b knock out mice were generated as described above. The Cpt1b knock 
out mice were then crossed with AY mice (Jackson Laboratory) in order to achieve the double 
mutated mice.   
 
2.9. Confirmation of Genotype 
 
Mouse DNA is obtained from tail end snips or ear punches. Snips are digested using a tail 
lysis buffer. Following digestion, DNA is isolated through a series of separations with columns 
using centrifugation. DNA is amplified via polymerase chain reaction (PCR), then run on an 
agarose gel. Upon completion of electrophoresis, the gel is imaged using the Image Lab 4.0.1 
Software.    
 
 
 
Figure 1. Genotyping for Cre and Cpt1b. This gel image demonstrates how mice are genotyped 
for cre recombinase and floxed Cpt1b.  
 
Knock out mice are confirmed by checking for cre recombinase and lox P sites. When 
checking for cre, an internal processing control (IPC) is used in order to reduce the chances of 
false negatives. Therefore, all mice should show a band at 320bp which is indicative of the IPC. 
The IPC amplicon is added to the extracted DNA for each sample before the DNA is added to 
the well of the gel. For detection of the cre gene, forward and reverse primers for the cre gene are 
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used to produce amplicons with the size of 166 bp. Therefore, cre positive mice will show an 
additional band at 166bp and cre negative mice will show nothing other than the IPC at 320bp.  
When checking for lox P sites, forward and reverse primers for the Cpt1b gene with the start of 
the primers coming before the insertion points of loxP are used. Control mice with no lox P sites 
will show one band at 360bp. Floxed mice (mice with target DNA sequence sandwiched between 
2 lox P sites) will show one band at 460bp. Heterozygous mice will show one band at 360bp and 
another band at 460bp.   
 
2.10. Sable Systems Promethion 
 
Mice were put in the Sable Systems International promethion for 1 week. Food and water 
uptake and respiratory quotient measurements were taken every 5 minutes while in the 
promethion chamber.   
 
2.11. Statistical Analysis 
 
Data were analyzed by t test if normally distributed with an n of at least 8. If data failed 
D’Agostino-Pearson test for normality or had an n less than 8, the Mann Whitney test was run. 
Tests were run using GraphPad Prism 7 software. JMP software from SAS was used for the 
linear regression analysis. The P value was set at <0.05 a priori. 
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Results 
 
When mitochondrial fatty acid oxidation is inhibited in skeletal muscle by knocking out 
Cpt1b, the expression of genes involved in mitochondrial fatty acid oxidation is expected to be 
upregulated in skeletal muscle. This model would also suggest a build-up of lipid in skeletal 
muscle. To confirm these expectations, the expression of genes involved in mitochondrial fatty 
acid oxidation, transport, binding and storage were all measured.   
 
3.1. Cpt1b Deficiency Encapsulates a Model of Lipid Accumulation and FAO Impairment. 
Increase in the Release of Fatty Acids in Circulation 
 
Impaired fatty acid oxidation in skeletal muscle was achieved by knocking out Cpt1b, the 
rate-limiting enzyme of the long-chain fatty acid beta-oxidation (FAO) pathway in muscle 
mitochondria. Expression of genes involved in mitochondrial fatty acid oxidation, Hydroxyacyl-
CoA dehydrogenase and Enoyl-CoA hydratase 1 (Hadha and Ech1), were significantly elevated 
in the gastrocnemius of AY:Cpt1bm-/- mice relative to control mice (Figure 2A). The Hadha gene 
is responsible for constructing part of the enzyme complex referred to as mitochondrial 
trifunctional protein. This complex consists of 3 enzymes which are all essential for fatty acid 
oxidation. Ech1 enzyme functions in the auxiliary step of the fatty acid B-oxidation pathway. In 
addition to this, expression of genes involved in fatty acid transport (Cd36 and Fatp1), binding 
(Fabp3) and storage (Plin5) were also upregulated in the gastrocnemius of AY:Cpt1bm-/- mice 
relative to controls and AY mice (Figure 2B and 2C). CD36, also known as fatty acid translocase, 
is responsible for long-chain fatty acid transport in muscle cells. Fatty acid transport protein 1 
(Fatp1) serves as an enhancer of cellular uptake of long-chain fatty acids. Fatty acid binding 
protein 3 (Fabp3) is believed to participate in uptake, metabolism and transport of long-chain 
fatty acids. Perilipin-5 (Plin5) coats the surface of lipid droplets and serves as a barrier which 
provides increased storage capacity. Taken together, we believe this data displays skeletal 
muscle specific ablation of Cpt1b as a model of FAO impairment and lipid accumulation in 
genetically obese AY:Cpt1bm-/- mice.  
 
A.)                                                               B.)             
 
fig cont’d 
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Figure 2. Lipid Accumulation and FAO Impairment in Skeletal Muscle. 
A.) Mitochondrial fatty acid oxidation genes are significantly elevated in AY and AY:Cpt1bm-/- 
mice relative to control mice. B.) Fatty acid transport, binding and storage genes are upregulated 
in the gastrocnemius of AY:Cpt1bm-/- mice relative to control and AY mice. C.) Binding and 
storage genes are upregulated in the gastrocnemius of AY:Cpt1bm-/- mice relative to control and 
AY mice. Significance was set at a p < 0.05. n=4-10.  
 
With mitochondrial fatty acid oxidation (FAO) being inhibited in skeletal muscle, we 
wanted to know if peroxisomal FAO was compensating for the lack of mitochondrial FAO. We 
were also interested in seeing if other fuel sources were being used in place of fat. We decided to 
measure the expression of genes involved with peroxisomal fatty acid oxidation and amino acid 
catabolism.   
 
3.2. Mitochondrial Biogenesis, Peroxisomal FAO and Amino Acid Catabolism are 
Upregulated in Gastrocnemius of AY:Cpt1bm-/- Mice Relative to AY Mice 
 
Skeletal muscle of AY:Cpt1bm-/- mice appears to become more heavily reliant on 
peroxisomes for fatty acid oxidation. Peroxisomes are organelles that specialize in the oxidation 
of a wide variety of fatty acids. Acyl-coenzyme A oxidase 1 (Acox1) is an enzyme responsible 
for performing B-oxidation of fatty acids in the peroxisomes of cells and its expression was 
found to be upregulated in the gastrocnemius of AY:Cpt1bm-/- mice (Figure 3A). Additionally, 
skeletal muscle of AY:Cpt1bm-/- mice appear to use alternative sources of fuel for energy. For 
example, branched-chain alpha-keto acid dehydrogenase and branched chain amino acid 
transaminase 2 (Bckdha1 and Bcat2), are both involved in the catabolism of branched chain 
amino acids and are found to be upregulated in the gastrocnemius of AY:Cpt1bm-/- mice (Figure 
3B).  
 
 
 
 
 
 
 
 
 
C.) 
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A.)                        B.)                                                                                                                    
                                                                                                                                   
 
Figure 3. Adaptations Made in Skeletal Muscle 
A.) Peroxisomal fatty acid oxidation is significantly elevated in the AY:Cpt1bm-/- mice relative to 
control and AY mice. B.) Amino acid oxidation is significantly upregulated in AY:Cpt1bm-/- mice 
relative to controls and AY mice. Significance was set at a p < 0.05. n=4-10.  
 
We were interested in looking at caloric intake for these mice. Calorimetry data were 
obtained by housing mice in single-caged promethion chambers for a week long period. Food 
and water consumption were measured. Cpt1bm-/- mice have previously been shown to eat 
significantly less relative to control mice when fed a 25% fat diet (Warfel et al., 2017). 
Therefore, we wanted to see if AY:Cpt1bm-/- mice behaved similarly when fed a 25% diet. 
 
3.3. AY Mice ate more Food and Drink more Water Relative to AY:Cpt1bm-/- Mice 
 
AY mice ate significantly more food than the AY:Cpt1bm-/- mice (Figure 4A). AY mice 
also consumed significantly more water relative to Control and AY:Cpt1bm-/-  mice (Figure 4B).  
 
A.)               B.)   
 
 
Figure 4. Food and Water Intake  
A.) AY mice consumed significantly higher amounts of food relative to AY:Cpt1bm-/- mice. B.) 
Water intake for AY mice was also significantly higher relative to Control and AY:Cpt1bm-/- mice. 
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Body composition was measured over an 18-week period using a Bruker NMR Minispec. 
Lean mass was lower in the AY:Cpt1bm-/- mice relative to AY mice which may explain their 
decrease in food and water intake. Previously, Cpt1bm-/- mice were shown to have a decrease in 
food intake relative to controls when fed a 25% fat diet. This decrease in food intake was due to 
a decrease in lean mass. Cpt1bm-/- had less lean mass; therefore, they were consuming less 
energy. However, Cpt1bm-/- were shown to maintain control levels for lean mass when fed a 10% 
diet. It was suggested that skeletal muscle Cpt1b knock out may cause an aversion to fat in the 
diet (Warfel et al., 2017).   
 
3.4. Compared to AY Mice, AY:Cpt1bm-/- Mice Have Only Numerically Lower Body Weight, 
Fat Mass and  Lean Mass 
 
Compared to AY mice, AY:Cpt1bm-/- mice had numerically lower body weights, but 
differences were not significant (Figure 5A). As the length of the study increased in weeks, this 
numerical difference increased. Significance was likely not obtained because of the relatively 
small number of mice and variability. Fat mass for AY:Cpt1bm-/- mice had a numerical difference 
with lower levels than for AY mice only for the eighteenth week (Figure 5B). Lean mass for 
AY:Cpt1bm-/- mice was also numerically lower than for AY mice from ten through eighteen weeks 
of the study  (Figure 5C). These results indicate that studies with greater numbers of mice may 
result in statistical differences.   
 
A.)        B.) 
                                            
C.)                                                             
 
 
Figure 5. Food and Water Intake 
A.) Over an 18 week timeline, AY:Cpt1bm-/- mice had numerically lower body weight in 
comparison to AY mice; however, no significant difference was noted between groups. Both 
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groups were significantly heavier than Control mice. B.) Fat mass for the AY:Cpt1bm-/- mice was 
also numerically below AY mice. Both groups had significantly more fat mass than Control mice. 
C.) Lean mass for the AY:Cpt1bm-/- mice was numerically lower than AY mice. AY mice had 
significantly more lean mass than Control mice. Significance was set at a p < 0.05. n=6-13.  
 
Despite minimal changes in fat mass and body weight for AY:Cpt1bm-/- mice relative to 
AY mice, we did find a rather remarkable improvement in glucose clearance and insulin 
sensitivity. Taken together, these findings suggest a metabolically healthy, yet obese state for the 
AY:Cpt1bm-/- mouse model. 
 
3.5. AY:Cpt1bm-/- Mice Have Improved Insulin Resistance and Glucose Clearance 
Compared to AY Mice 
 
Remarkably, despite minimal changes in body weight and composition, AY:Cpt1bm-/- 
mice performed significantly better on glucose clearance and insulin sensitivity tests. At 13-
weeks-of-age, AY:Cpt1bm-/- mice achieved significantly better results relative to AY mice during 
a glucose tolerance test (GTT) (Figure 6A). Performance during an insulin tolerance test (ITT) at 
14-weeks-of-age improved significantly in AY:Cpt1bm-/- mice relative to AY mice (Figure 6B). 
AY:Cpt1bm-/- mice managed to return to control levels for both tests (GTT and ITT) while blood 
glucose levels remained elevated in AY mice. Insulin levels were checked in 32-week-old mice in 
the fasted state and AY mice had significantly higher fasted insulin levels relative to control and 
AY:Cpt1bm-/- mice. Insulin levels for AY:Cpt1bm-/- mice were returned to control levels (Figure 
6C).  
 
A.)         B.) 
 
 
 
 
 
 
 
 
 
 
 
fig cont’d 
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C.) 
 
 
Figure 6. Glucose Tolerance and Insulin Sensitivity 
A.) AY:Cpt1bm-/- mice performed significantly better on glucose tolerance testing (GTT) in 
comparison to AY mice at 13 weeks of age. B.) At 14 weeks of age, AY:Cpt1bm-/- mice performed 
significantly better during insulin tolerance testing compared to AY mice. C.) Insulin was 
measured in serum using an ultra-sensitive mouse insulin ELISA kit. Samples were from 32-
week-old mice in the fasted state. AY:Cpt1bm-/- mice had significantly less circulating insulin in 
comparison to AY mice. Significance was set at a p < 0.05. n=4-13.  
 
In an attempt to better understand the reason for these improvements in glucose clearance 
and insulin sensitivity, the expression of Fgf21 and Pgc1a was measured in skeletal muscle. 
Fgf21 was measured because it has been shown previously to be contributing to the improvement 
in glucose clearance and insulin sensitivity seen in the Cpt1bm-/- mice. Pgc1a was measured to 
assess if mitochondrial biogenesis was upregulated in skeletal muscle. If more mitochondria 
were present, this may offer an explanation for improved glucose clearance.   
 
3.6. AY:Cpt1bm-/- Mice Have Elevated Fgf21 and Pgc1a in Skeletal Muscle Relative to AY 
Mice. 
 
 Fibroblast growth factor 21 (Fgf21) is elevated in the gastrocnemius of AY:Cpt1bm-/- 
mice (Figure 6A). Fgf21 has been shown as being partially responsible for enhanced glucose 
clearance in Cpt1bm-/- mice. With a similar result seen in AY:Cpt1bm-/- mice, we assume Fgf21 
likely plays a role in the insulin sensitizing effect seen in the double mutant mouse model. 
Cpt1bm-/- mice appear to acclimate to the muscle specific ablation with favorable adaptations 
such as increased mitochondrial biogenesis. Peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha, Pgc1a, is a transcriptional coactivator that serves as a central inducer in 
mitochondrial biogenesis and it is significantly elevated in gastrocnemius muscle of AY:Cpt1bm-/- 
mice relative to control and AY mice (Figure 7B). 
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A.)       B.) 
  
 
Figure 7. Skeletal Muscle Fgf21 and Pgc1a 
A.) At 32 weeks of age, Fgf21 expression in gastrocnemius is significantly elevated in 
AY:Cpt1bm-/- mice relative to Control and AY mice. B.) Mitochondrial biogenesis is significantly 
upregulated in the AY:Cpt1bm-/- mice relative to control and AY mice. Significance was set at a p 
< 0.05. n=4-9. 
 
In addition to improving glucose clearance and insulin sensitivity, Fgf21 is known for 
having a paradoxical effect in which its levels are elevated in the circulation of obese mice. 
Some have proposed obesity as an Fgf21 resistant state. We decided to evaluate this in our mice 
by using an Fgf21 Elisa kit to measure levels in fed serum. Since levels in the AY:Cpt1bm-/- mice 
were found to be numerically lower than AY levels, the skeletal muscle Cpt1b knock out may be 
responsible for lower levels in circulation and suggestive of improved overall utilization of 
Fgf21. 
 
3.7. Fgf21 is Elevated in Serum of 32 Week Old AY:Cpt1bm-/- Mice in the Fed State Relative 
to Control Mice, but Less than AY Mice  
 
Fgf21 was found to be significantly elevated in the serum of AY mice in the fed state 
relative to control mice (Figure 8). This elevation in serum may be indicative of Fgf21 resistance 
in the genetically obese AY mice. As seen in Figure 7, the Fgf21 in fed serum of AY mice does 
not appear to be coming from skeletal muscle. Rather, the primary source of Fgf21 in AY mice 
appears to be from hepatic production. Fgf21 was elevated in the gastrocnemius and liver for 
AY:Cpt1bm-/- mice; however, Fgf21 in fed serum was not significantly elevated in AY:Cpt1bm-/- 
mice. Therefore, muscle specific knockout of Cpt1b may help avoid Fgf21 resistance and 
promote insulin sensitivity.  
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Figure 8. Fgf21 in Circulation 
Fgf21 is increased in serum of 32 week old AY:Cpt1bm-/- mice relative to Control, but decreased 
relative to AY mice, which could suggest Fgf21 resistance in AY mice, while not in AY:Cpt1bm-/- 
mice. Significance was set at a p < 0.05. n=3-9.  
 
While improvements in glucose clearance and insulin sensitivity are heavily notable in 
the AY:Cpt1bm-/- mice, we also observed a significant decrease in their liver weights relative to 
AY mice. This decrease in weight could be suggestive of improved hepatic health relative to AY 
mice. Further investigation will be needed to confirm this assumption. 
 
3.8. Liver Weight is Decreased in AY:Cpt1bm-/- Mice Relative to AY Mice 
 
Liver weights were drastically decreased in AY:Cpt1bm-/- mice relative to AY mice (Figure 
9). Differences in weights are further discussed in Figure 10. 
  
 
Figure 9. Liver Weight 
 Liver weights of AY:Cpt1bm-/- mice were significantly lower than liver weights of AY mice. 
Significance was set at a p < 0.05. n=4-10.  
 
With liver weight being significantly lower in AY:Cpt1bm-/- mice relative to AY mice, we 
began to wonder what was accounting for this difference in weight. Since liver is an important 
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storage site for glycogen, we decided to assess hepatic glycogen levels to see if  storage was 
depleted in the livers of AY:Cpt1bm-/- mice relative to AY mice. We also assumed the liver may 
be compensating for the loss of fatty acid oxidation in the muscle and have less ectopic fat as a 
result. We decided to measure hepatic triglyceride levels. Additionally, lipid droplets were 
viewed in liver samples that were embedded in paraffin and sectioned and stained with H&E at 
the Cell Biology and Bioimaging Core Facility at Pennington Biomedical Research Center. 
 
3.9. Liver Glycogen and Triglycerides are Numerically Decreased in AY:Cpt1bm-/- Mice 
Relative to AY Mice According to Chemical Analyses, but Histology Samples Demonstrate 
Lower Fat Mass 
 
Triglycerides in the liver of 32-week-old mice were significantly elevated in AY mice 
relative to Control. Triglyceride levels in AY:Cpt1bm-/- mice were not significantly elevated 
relative to Control mice; however, the levels were not significantly less than AY mice. 
Triglycerides in the liver of AY:Cpt1bm-/- mice were numerically lower than for AY mice with the 
p value equaling 0.1531 (Figure 10A). Hepatic glycogen levels followed a similar trend between 
AY and AY:Cpt1bm-/- mice with AY:Cpt1bm-/- mice having lower glycogen amounts than AY mice 
without reaching significance (Figure 10B). The p value between these two groups was p = 
0.0952. While neither hepatic triglyceride or glycogen levels showed statistically significant 
differences between AY and AY:Cpt1bm-/- mice, AY:Cpt1bm-/- mice had numerically lower 
amounts and these numerical differences combined to result in a statistically significant 
difference in liver weight. Histology samples also show less ectopic lipid in the livers of 
AY:Cpt1bm-/- mice relative to AY mice (Figure 10C). Triglyceride content provides non-
conclusive evidence that fats are decreased in AY:Cpt1bm-/- liver relative to AY liver; however, 
other tissue levels such as white adipose, cholesterol and ceramide fat species still need to be 
quantified.  
 
A.)                                B.)  
                                          
 
 
 
 
 
fig cont’d 
20 
 
 
C.) 
      
       
 
Figure 10. Hepatic Triglycerides and Glycogen Levels and Histology Images  
A.) Liver triglycerides levels were numerically lower in the livers of AY:Cpt1bm-/- mice when 
compared to liver triglycerides of AY mice; however, there was no statistical significance. B.) 
Liver glycogen levels were also lower in AY:Cpt1bm-/- mice when compared to liver glycogen 
levels of AY mice; however, there was also no statistical significance. C.) Liver histology images 
(5x magnification) show more ectopic fat accumulation in the AY mice relative to the 
AY:Cpt1bm-/- mice. Significance was set at a p < 0.05. n=3-8.  
 
While triglyceride and glycogen levels were numerically lower in AY:Cpt1bm-/- mice 
relative to AY mice, we did not think this was enough to account for the difference in liver 
weights. Therefore, we decided to assess hepatic fluid levels as well.  
 
3.10. Liver Contains Less Fluid Mass in AY:Cpt1bm-/- Mice Relative to AY Mice 
 
In addition to hepatic triglyceride and glycogen levels being numerically lower in 
AY:Cpt1bm-/- mice compared to AY mice, hepatic fluid levels were significantly greater for AY 
mice (Figure 11A). A correlation plot between fluid and triglyceride + glycogen content 
generated an R2 value of 0.5; therefore, numerically greater triglyceride and glycogen amounts 
appear to promote greater fluid retention (Figure 11B).  
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A.)                 B.)  
           
 
Figure 11. Hepatic Fluid and Fluid Retention Correlation Plot 
A.) Liver fluid levels of AY:Cpt1bm-/- mice were significantly less than liver fluid levels of AY 
mice. B.) Correlation plot between triglycerides + glycogen and fluid had a R2 value of 0.5. 
Significance was set at a p < 0.05. n=4-10.  
 
As seen previously in Figure 10C, histology images seem to reveal lower amounts of 
ectopic fat in the livers of AY:Cpt1bm-/- mice relative to AY mice. To further assess this finding, 
we decided to measure the expression of several genes involved in fatty acid synthesis.   
 
3.11. Fatty Acid Synthesis Pathways Are Decreased in the Liver of AY:Cpt1bm-/- Mice 
Relative to AY Mice  
 
Expression of enzymes involved in fatty acid synthesis was significantly upregulated in 
the liver of AY mice relative to Control and AY:Cpt1bm-/- mice at 16-weeks-of-age. Acetyl-CoA 
carboxylase (Acaca), the enzyme responsible for catalyzing the carboxylation of acetyl-CoA to 
malonyl-CoA, is significantly upregulated in the liver of AY mice relative to Control mice at 16-
weeks-of-age. It is also increased in AY:Cpt1bm-/- mice relative to Control mice; however, 
AY:Cpt1bm-/- expression trends less than AY mice (Figure 12A). Fatty acid synthase (Fasn), the 
enzyme involved with catalyzing the synthesis of palmitate from acetyl-CoA and malonyl-CoA, 
is significantly upregulated in the livers of AY mice relative to Control and AY:Cpt1bm-/- mice at 
16-weeks-of-age (Figure 12B). Stearoyl-CoA desaturase (Scd1), the enzyme primarily 
responsible for the synthesis of oleic acid, is upregulated in the liver of AY mice relative to 
Control and AY:Cpt1bm-/- mice at 16-weeks-of-age (Figure 12C). At 32-weeks-of-age, expression 
of enzymes involved in fatty acid synthesis (Fasn and Scd1) were numerically greater in livers of 
AY mice relative to Control and AY:Cpt1bm-/- mice (Figure 12D and 12E). However, Acaca was 
significantly elevated in AY mice relative to Control mice, but only numerically higher than 
AY:Cpt1bm-/- mice at 32-weeks-of-age (Figure 12F). Expression of these enzymes appears to 
increase with age for all groups with upregulation occurring earlier in AY mice. Expression 
appears to remain higher in AY mice relative to all groups despite age. However, for the most 
part, the higher amounts were not significantly different. While not significant (likely due to low 
n with relatively high variability), these data may still be suggestive of elevated fatty acid 
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synthesis in the livers of AY mice relative to AY:Cpt1bm-/- mice. Additional studies with a larger 
number of mice per group are needed to confirm elevated levels in AY mice at 32 weeks of age.  
 
A.)                                                                            B.)        
C.) D.)   
  
E.)         F.) 
      
 
Figure 12. Hepatic Fatty Acid Synthesis 
A.) Acetyl-CoA carboxylase alpha (Acaca) is significantly elevated in livers of 16-week-old AY 
mice relative to Control and AY:Cpt1bm-/- mice. Acaca is also significantly elevated in 
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AY:Cpt1bm-/- mice relative to Control. B.) Fatty acid synthase (Fasn) is significantly elevated in 
livers of 16-week-old AY mice relative to Control and AY:Cpt1bm-/- mice. C.) Stearoyl-CoA 
Desaturase (Scd1) is significantly elevated in livers of 16-week-old AY mice relative to Control 
and AY:Cpt1bm-/- mice. These data may be suggestive of elevated fatty acid synthesis in the livers 
of AY mice relative to AY:Cpt1bm-/- mice. D.) Hepatic Fasn was numerically higher in AY mice 
relative to control and AY:Cpt1bm-/- at 32 weeks of age. E.) Hepatic Scd1 was numerically higher 
in AY mice relative to control and AY:Cpt1bm-/- at 32 weeks of age. F.) Acaca is significantly 
elevated in the livers of 32-week-old AY mice relative to Control mice and is numerically higher 
in AY mice relative to AY:Cpt1bm-/- mice. Significance was set at a p < 0.05. n=4-9. 
 
Additionally, we wanted to check if mitochondrial and peroxisomal fatty acid oxidation 
was upregulated in the livers of AY:Cpt1bm-/- mice relative to AY mice. We decided to measure 
hepatic gene expression of genes involved with mitochondrial and peroxisomal fatty acid 
oxidation.  
 
3.12. Hepatic Mitochondrial and Peroxisomal Fatty Acid Oxidation is Increased in the 
Liver of AY:Cpt1bm-/- Mice Relative to AY Mice 
 
A.)                                                                           B.) 
         
C.)                                                                                             D.) 
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Figure 13. Hepatic Fatty Acid Oxidation  
A.) Ech1 was significantly upregulated in the liver of AY:Cpt1bm-/- mice relative to Control mice. 
B.) Hadha was significantly upregulated in the liver of AY:Cpt1bm-/- mice relative to Control 
mice. C.) Cpt1a was found to be was found to be significantly elevated in the liver of 
AY:Cpt1bm-/- mice relative to Control and AY mice. D.) Acox1, involved with peroxisomal fatty 
acid oxidation, was also found to be significantly elevated in the liver of AY:Cpt1bm-/- mice 
relative to Control and AY mice . 
 
Mitochondrial and peroxisomal fatty acid oxidation may be elevated in the liver of 
AY:Cpt1bm-/- mice to compensate for the inhibition of mitochondrial fatty acid oxidation in 
skeletal muscle. Respiratory quotient (RQ) data obtained from the promethion chambers show 
AY:Cpt1bm-/- mice maintaining lower RQ’s relative to AY mice (Figure 14). This RQ data appears 
to indicate that AY:Cpt1bm-/- mice are burning more fat for fuel relative to AY mice. Additionally, 
genes involved with mitochondrial and peroxisomal fatty acids were found to be up in the liver 
of AY:Cpt1bm-/- mice. Taken together, these data may suggest increased reliance on fat for fuel 
and consequentially reduced ectopic fat in the liver of AY:Cpt1bm-/- mice. 
 
3.13. Respiratory Quotient is Lower for AY:Cpt1bm-/- Mice Relative to AY Mice  
 
A.)                                                                            B.) 
 
Figure 14. Respiratory Quotient  
A.) The respiratory quotient for AY:Cpt1bm-/- mice remains lower than that of AY mice, 
suggesting a higher dependence on fat as a fuel source. B.) This graph displays only RQ’s of AY 
and AY:Cpt1bm-/- mice. 
 
In addition to a lower RQ and increased hepatic mitochondrial and peroxisomal fatty acid 
oxidation, hepatic gluconeogenesis was also found to be elevated in the liver of AY:Cpt1bm-/- 
mice. 
 
3.14. Based on an Increase in Amounts of the Major Regulatory Gene for Gluconeogenesis, 
This Pathway for Glucose Synthesis Appears to be Increased in the Liver of AY:Cpt1bm-/- 
Mice Relative to AY Mice 
 
Noteworthy, phosphoenolpyruvate carboxykinase (Pck1), the major regulatory 
gluconeogenic enzyme, is significantly upregulated in 32-week-old liver of AY:Cpt1bm-/- relative 
to Control and AY mice (Figure 15). The reason for this is unknown but may indicate that they 
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are making more glucose to supply it for skeletal muscle. Additionally, the AY:Cpt1bm-/- mice 
may also have an increased need for glucose for energy.   
 
A). 
 
 
Figure 15. Hepatic Gluconeogenesis  
A.) Gluconeogenesis appears to be significantly elevated in the livers of AY:Cpt1bm-/- mice in 
comparison to AY mice. Significance was set at a p < 0.05. n=4-6.  
 
Triglycerides were significantly reduced in the serum of AY:Cpt1bm-/- mice relative to AY 
mice. Hepatic triglycerides were not significantly different between groups (Figure 10A); 
however, significantly less triglycerides are released into circulation for AY:Cpt1bm-/- mice 
relative to AY mice. Previous research has shown Gdf15 to increase the release of hepatic 
triglycerides into circulation (Luan et al., 2019). Expression of Gdf15 was found to be 
upregulated in the liver of AY mice relative to AY:Cpt1bm-/- mice and may explain the significant 
increase in circulating triglycerides.  
 
3.15. Gdf15 is Upregulated in the Liver of AY Mice Relative to All Groups and May 
Explain the Increase in the Release of Fatty Acids in Circulation 
 
At 16-weeks-of-age growth differentiation factor 15 (Gdf15) was significantly elevated in 
AY mice relative to Control and AY:Cpt1bm-/- mice (Figure 16A). At 32-weeks-of-age, Gdf15 was 
numerically higher than Control (p=0.054) and AY:Cpt1bm-/- mice; however, no significance was 
noted (Figure 16B). Triglycerides in serum of mice fasted for 4-hours were significantly higher 
in AY mice relative to Control and AY:Cpt1bm-/- mice. Levels for AY:Cpt1bm-/- mice were 
significantly lower than for Control mice (Figure 16C). The elevated expression of hepatic Gdf15 
in AY mice may be partially responsible for the increase in triglyceride circulation.  
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A.)        B.)  
 
C.)  
  
 
Figure 16. Hepatic Gdf15 and Triglycerides in Circulation   
A.) Hepatic Gdf15 expression in AY mice is significantly higher than for Control and AY:Cpt1bm-
/- mice at 16-weeks of age. B.) Hepatic Gdf15 expression in AY mice is numerically higher than 
for Control and AY:Cpt1bm-/- mice at 32-weeks of age. C.) Triglycerides in serum of mice fasted 
for 4 hours was significantly lower in AY:Cpt1bm-/- mice relative to Control and AY mice. 
Significance was set at a p < 0.05. n=4-10.  
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Table 2. Summary of Results. 
 
Measurements Results 
Promethion Data AY:Cpt1bm-/- Relative to AY 
Food Intake ↓ 
Water Intake ↓ 
Respiratory Quotient ↓ 
Muscle Metabolism mRNA AY:Cpt1bm-/- Relative to AY 
Mitochondrial Fatty Acid Oxidation ↑ 
Fatty Acid Transport, Binding and Storage ↑ 
Peroxisomal Fatty Acid Oxidation  ↑ 
Amino Acid Catabolism ↑ 
Mitochondrial Biogenesis  ↑ 
Fgf21 ↑ 
Hepatic mRNA AY:Cpt1bm-/- Relative to AY 
Gluconeogenesis ↑ 
Gdf15 ↓ 
Fatty Acid Oxidation ↑ 
Fatty Acid Synthesis ↓ 
Metabolic Health AY:Cpt1bm-/- Relative to AY 
Improved Glucose Utilization 
 
Improved Insulin Sensitivity 
 
Decreased Body Weight 
 
Decreased Fat Mass 
 
Decreased Lean Mass 
 
 
table cont’d.  
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Measurements Results 
Promethion Data AY:Cpt1bm-/- Relative to AY 
Fgf21 ↓ 
Insulin ↓ 
Triglycerides ↓ 
Liver AY:Cpt1bm-/- Relative to AY 
Weight ↓ 
Triglycerides ↓ 
Glycogen ↓ 
Fluid ↓ 
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Discussion 
 
4.1. Improvements in Metabolic Health 
 
Inhibition of long chain fatty acid B-oxidation in the mitochondria of skeletal muscle has 
rescued the metabolic health of genetically obese AY mice. Despite minimal changes in fat mass 
and body weight, AY:Cpt1bm-/- mice drastically improve their performance during  glucose 
tolerance testing and insulin tolerance testing. In comparison to AY mice, AY:Cpt1bm-/- mice have 
significantly lower amounts of insulin and triglycerides in the circulation of 32-week-old mice in 
the fasted state. Gene expression for enzymes involved with fatty acid synthesis were down in 
the livers of AY:Cpt1bm-/- mice relative to AY mice and may explain the decrease in circulating 
triglycerides. Additionally, hepatic triglycerides were numerically lower in AY:Cpt1bm-/- mice 
relative to AY mice and histology liver images appear to show a decrease in ectopic lipid 
accumulation for AY:Cpt1bm-/- mice. Liver weights for AY:Cpt1bm-/- mice were significantly 
lower than that of AY mice. Taken together, these data are suggestive of improved metabolic and 
hepatic health in AY:Cpt1bm-/- mice even though there were minimal changes in fat mass and 
body weight. The reason why Cpt1bm-/- mice exhibit a leaner phenotype is still under 
investigation; however, Agouti mice must be blocked from having the effects of these anorectic 
factors. The blocking may be due to the presence of the agouti protein. Further investigation is 
needed in order to unmask the lingering questions of why Cpt1bm-/- mice become leaner when 
long chain fatty acid B-oxidation is inhibited in skeletal muscle mitochondria and what is 
preventing Agouti mice from doing the same.    
 
4.2. Modifications Occurring in Skeletal Muscle of AY:Cpt1bm-/- Mice 
 
Skeletal muscle-specific Cpt1b knock out in genetically obese AY mice appear to strongly 
embody a model of lipid aggregation and FAO impairment. Expression of genes involved with 
fatty acid binding (Fabp3), lipid droplet forming (Plin5) and fatty acid transport (Cd36, Fatp1) 
were all significantly increased in gastrocnemius muscle of AY:Cpt1bm-/- mice. Expression of 
Hadha and Ech1, genes associated with mitochondrial FAO, were significantly upregulated in 
AY:Cpt1bm-/- mice relative to Control mice. Furthermore, peroxisomal FAO appears to 
compensate for impairment of mitochondrial FAO in muscle. Acyl-CoA oxidase 1 (Acox1), a 
peroxisomal FAO gene, was found to be upregulated in AY:Cpt1bm-/- mice. Inhibition of fatty 
acid oxidation appears to result in usage of alternative fuel sources in muscle. Bckdha and Bcat2, 
genes associated with mitochondrial branched-chain amino acid cycle, were elevated in the 
gastrocnemius of AY:Cpt1bm-/- mice.  
As seen previously in muscle of Cpt1bm-/- mice, muscle of AY:Cpt1bm-/- mice appear to 
undergo a plethora of effects that could be induced by an energy deficit signal elicited from 
inhibition of B-oxidation. AMP-activated protein kinase (AMPK) is a sensor of cellular energy 
status that becomes activated with a high ratio of AMP:ATP in the cell. AMPK is a promoter of 
glucose uptake, fatty acid oxidation, mitochondrial biogenesis and insulin sensitivity (O'Neill, 
2013). Previous work with Cpt1bm-/- mice found a significant increase in the phosphorylation of 
the α-subunit of AMPK at Thr-172 relative to control mice. Additionally, AMPK target 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Pgc1α) was found to be 
robustly elevated in both red and white muscles (S. E. Wicks et al., 2015). Pgc1α is often 
accredited as a master in the regulation of mitochondrial biogenesis and was elevated in 
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AY:Cpt1bm-/- mice. This suggests that there may be more mitochondria in the skeletal muscle of 
mice with the skeletal-muscle specific Cpt1b knock out. Increases in the number of mitochondria 
in skeletal muscle may be partially responsible for improved glucose utilization. While Pgc1α 
expression in gastrocnemius was found to be elevated in both Cpt1bm-/- and AY:Cpt1bm-/- mice, 
phosphorylation of the α-subunit of AMPK at Thr-172 was never measured in AY:Cpt1bm-/- mice. 
Given that AY:Cpt1bm-/- mice have increased mitochondrial biogenesis in gastrocnemius, 
improved glucose clearance and enhanced insulin sensitivity, we hypothesize the 
phosphorylation of the α-subunit of AMPK at Thr-172 would follow a similar pattern in 
AY:Cpt1bm-/- mice relative to Cpt1bm-/- mice. Additional work will be needed to confirm this 
hypothesis.  
 
4.3. The Impact of Fgf21 
 
Expression of Fgf21 was elevated in the muscle of AY:Cpt1bm-/- mice. A double knockout 
mouse model of Cpt1b and Fgf21 showed a partial negation in improved glucose utilization in 
comparison to Cpt1b knock outs (Vandanmagsar et al., 2016). Fgf21 may be somewhat 
responsible for the increase in glucose utilization when Cpt1b is knocked out in skeletal muscle. 
However, there are definitely other factors contributing to these improvements and the relevance 
of the physiological effects Fgf21 has on improved metabolic health in skeletal-muscle specific 
Cpt1b knock out mice may be questionable. Transcriptomics and proteomic analyses could 
potentially identify other contenders contributing to the improvements on metabolic health in 
skeletal-muscle specific Cpt1b knock out mice.  
Fgf21 in the serum of mice in the fed state was significantly elevated for AY mice relative 
to Control mice, but there was not statistical significance between AY:Cpt1bm-/- mice and Control 
mice. Elevated Fgf21 serum levels have been observed in genetically and diet-induced obese 
mouse models. One study suggested that obesity is an Fgf21-resistant state. Their study 
evaluated the response of obese mice to administration of exogenous Fgf21 and noted a 
significantly reduced signaling response in diet-induced obese mice. They concluded by stating 
diet-induced obesity results in elevated endogenous Fgf21 levels and poor response to 
administration of exogenous Fgf21 (Fisher & Maratos-Flier, 2016). It is a possibility that the AY 
mice are experiencing an Fgf21 resistant state and AY:Cpt1bm-/- mice remain sensitive to Fgf21 
via inhibition of skeletal muscle FAO, allowing for improved glucose utilization. However, this 
suggestion needs further investigation. 
  
4.4. Investigation of Decreased Liver Weight in AY:Cpt1bm-/- Mice 
 
Liver weights for AY:Cpt1bm-/- mice were significantly less than AY liver weights. 
Triglyceride and glycogen content were numerically lower in AY:Cpt1bm-/- mice and fluid levels 
were significantly less than AY mice. The correlation plot between fluid and glycogen + 
triglyceride content showed an R2 value of 0.5. Increased amounts of triglycerides and glycogen 
content in the liver may be partially contributing to the increased fluid levels seen in the livers of 
AY mice. Increased fluid retention in the liver may also be suggestive of hepatic inflammation. 
Checking inflammatory biomarkers in the liver could potentially help with explaining the higher 
fluid levels seen in the AY mice. 
Also, gene expression of various enzymes involved in fatty acid synthesis was 
upregulated in the livers of AY mice. Histology images show a larger amount of lipid 
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accumulation in AY liver relative to AY:Cpt1bm-/- liver. Taken together, these data suggest 
improvements in ectopic lipid accumulation in AY:Cpt1bm-/- liver relative to AY liver. These data 
also indicate that the addition of the Cpt1bm-/- to the AY heterozygote genotype results in a 
moderate, but important improvement in handling dietary energy.  
 
4.5. Lower Respiratory Quotient in AY:Cpt1bm-/- Mice Relative to AY Mice 
 
Pck1 was significantly elevated in the livers of AY:Cpt1bm-/- mice suggesting an 
upregulation in hepatic gluconeogenesis. Coupled with numerically lower liver glycogen, the 
increased amounts of liver Pck1 and decreased FAO indicate that the glucose product of 
gluconeogenesis is being used for energy in the AY:Cpt1bm-/- mice. Despite these findings, the 
respiratory quotient for AY:Cpt1bm-/- mice was less than that of AY mice. This would suggest that 
the AY:Cpt1bm-/- mice were actually utilizing more fat for fuel relative to AY mice. Since the AY 
mice are hyperglycemic, they may have a higher RQ because glucose is more readily available 
for use. Additionally, enzymes involved with amino acid oxidation were upregulated in the 
skeletal muscle of AY:Cpt1bm-/- mice, suggesting an increase in the reliance on protein as a fuel 
source. Protein may be contributing to the decreased RQ seen in the AY:Cpt1bm-/- mice; however, 
it is likely to be minimal.  
 
4.6. Possible Impact of Gdf15 
 
Circulating triglycerides in serum of AY:Cpt1bm-/- mice fasted for 4 hours was found to be 
significantly less relative to AY mice. While hepatic triglycerides content in AY:Cpt1bm-/- mice 
were numerically lower than for AY mice, triglyceride content in circulation was significantly 
lower in AY:Cpt1bm-/- mice. Livers of AY:Cpt1bm-/- mice appear to be holding on to hepatic 
triglycerides rather than releasing into circulation, despite having numerically lower hepatic 
triglycerides. Interestingly, hepatic expression of Gdf15 was found to be upregulated in AY liver 
compared to the other groups of mice. Previous research has found that Gdf15 stimulated export 
of hepatic triglycerides into plasma serum (Luan et al., 2019). An increase in lipid levels in any 
specific tissue seems to correlate in the literature and in our models with an increase in the 
amount of Gdf15 released from tissue (Lee et al., 2017; Li, Zhang, & Zhong, 2018). In our 
model, AY mice have large amounts of ectopic lipid in the liver along with elevated expression of 
hepatic Gdf15 and elevated triglycerides in circulation. While not conclusive, lipid overload 
appears to lead to an induction of hepatic Gdf15 and could potentially be indicative of pathology.  
Gdf15 has also been found to help stimulate weight loss and improve glucose tolerance 
(Day et al., 2019). Gdf15 is known to behave similarly to Fgf21 in that both are stress induced 
hormones. Notably, Gdf15 and Fgf21 were found to follow the same pattern in gastrocnemius of 
all four mouse models included in this study. Given that Fgf21 has an established role in the 
improvement of metabolic health in Cpt1bm-/- mice (Vandanmagsar et al., 2016), this raises the 
question of whether or not similar results would be found in a double knock out mouse model of 
Cpt1b and Gdf15. If Gdf15 was found to have a similar affect as Fgf21 on Cpt1bm-/- mice, this 
would raise the question of why do different physiological conditions lead to the release of these 
hormones from different sources and what does the source suggest? Hepatic release of Gdf15 
could possibly be suggestive of pathology while skeletal muscle release might indicate a 
favorable adaptation. 
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4.7. Limitations and Suggestions for Future Work 
 
A large limitation to this pilot study is a low number of mice. Further investigation is 
needed with a larger number of mice per group. In future studies, the measurement of the 
phosphorylation of the α-subunit of AMPK at Thr-172 in AY:Cpt1bm-/- mice relative to Control 
and AY mice would further elaborate the metabolic effects of the skeletal muscle homozygote 
knock out of Cpt1b. Chemical analysis of triglycerides in the liver, serum and histology images 
of ectopic fat in the liver were the only lipid measure that we assessed. There are other lipids that 
we have not quantified but the triglyceride content provides evidence that fats were decreased in 
serum and liver. It would be worthwhile to have the hepatic histology images scanned in order to 
quantify the amount of lipid droplets shown in these images. We recommend that future studies 
should also quantify other fats in the liver and serum. Creation of a double knockout mouse 
model of skeletal muscle specific Cpt1bm-/- and Gdf15 is recommended to determine if Gdf15 
plays a favorable role in the improved glucose utilization in Cpt1bm-/- mice. In addition to this, 
creation of a liver specific Gdf15 knockout in AY mice is also recommended to determine if 
hepatic Gdf15 influences plasma triglyceride levels. Further investigation is needed to determine 
additional factors contributing to the improved metabolic health when Cpt1b is knocked out in 
skeletal muscle. Transcriptomics and proteomic analyses of AY and AY:Cpt1bm-/- mice would be 
worthwhile in order to determine potential transcriptomes and proteomes contributing to the 
ameliorated glucose utilization and insulin sensitivity.  
 
Previous transcriptomic analysis of Cpt1bm-/- mice showed that Gdf15 was upregulated 
relative to control mice. Cpt1bm-/- mice had significantly less fat mass and body weight relative 
to control mice. The reasons for this leaner phenotype are not fully understood; however, 
increases in Gdf15 may contribute to the decreases in fat mass and body weight. Gene expression 
showed that AY:Cpt1bm-/- mice also have increased expression of Gdf15 in skeletal muscle 
relative to AY mice. Given that Gdf15 is an anorectic hormone, one might expect this increase in 
expression to lead to weight loss in AY:Cpt1bm-/- mice relative to AY mice. However, differences 
in weight and fat mass were minimal and not significantly different between groups. This lack of 
weight loss might suggest that the ubiquitous expression of agouti is interfering with the 
signaling of Gdf15 with receptors in the brain. Gdf15 is known to bind to the Gfral receptor in 
the brain. We think Gdf15 may also signal additional receptors in the brain.  
We know the ubiquitous overexpression of agouti blocks the Mcr4, preventing alpha-
melanocyte stimulating hormone from binding and driving yellow obese syndrome in AY mice.  
We suspected that this blockage of Mcr4 by agouti could also be interfering with the signaling of 
Gdf15, thus preventing the anorectic implications of this hormone. However, Gdf15 has been 
found to reverse hyperphagia and obesity in a melanocortin 4 receptor deficient rat model (Hsu 
et al., 2017). Therefore, Gdf15 does not appear to signal the Mcr4 receptor. It is still possible that 
Gdf15 could signal other receptors in the brain besides Gfral and additional research is needed to 
determine this. If Gdf15 is found to be responsible for the leaner phenotype in the Cpt1bm-/- mice, 
then the lack of weight loss seen in the AY:Cpt1bm-/- mice may suggest that the overexpression of 
agouti is also somehow interfering with the signaling of Gdf15 in the AY:Cpt1bm-/- mice. Gdf15 
will need to be knocked out in Cpt1bm-/- mice to determine if it is responsible for any of the 
improvements in metabolic health seen in the Cpt1bm-/- mice. Additionally, if knocking out 
Gdf15 in Cpt1bm-/- mice results in diminished weight loss, then the next step would be to knock 
out Gfral in Cpt1bm-/- mice in order to determine if other receptors are involved in the signaling 
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of Gdf15. If knocking out Mcr4 in the brain of Cpt1bm-/- mice still resulted in a leaner phenotype, 
then this would be one way to further confirm that Gdf15 does not signal the Mcr4 receptor. The 
further investigation of the leaner phenotype found in Cpt1bm-/- mice could potentially help with 
furthering the understanding of Gdf15 signaling in the brain.  
 
4.8. Applications to the Treatment of Obesity and Diabetes 
 
Inhibition of long chain fatty acid B-oxidation has proven to be effective for improving 
insulin sensitivity and glucose utilization in two mouse models, including one model of genetic 
obesity. In fact, inhibition of skeletal muscle long chain fatty acid B-oxidation resulted in a 
leaner phenotype in regular C57BL/6 mice. Genetically obese AY mice managed to maintain 
their obesity despite inhibition of long chain fatty acid B-oxidation in skeletal muscle. Further 
investigation is needed to fully understand what causes and protects against a leaner phenotype 
in each of these models, respectively. As of now, inhibition of Cpt1b in skeletal muscle appears 
to offer a therapeutic target for the treatment of insulin resistance. Currently, the three known 
inhibitors of Cpt1 are Etomoxir, Oxfenicine and Perhexiline CPT-I. Unfortunately, it is hard for 
these inhibitors to specifically target skeletal muscle without negatively impacting the heart and 
liver as well. The potential for Cpt1b to serve as a pharmacological therapy for skeletal muscle 
insulin resistance is limited until the specificity of these inhibitors is established. Additional 
research will be needed in order to make this into an efficacious treatment plan. 
 
4.9. Concluding Thoughts 
 
In aggregate, our results showed Cpt1b inhibition in skeletal muscle to be efficacious 
from a treatment standpoint for improving insulin resistance even in the Agouti mouse model 
with severe obesity and diabetes, despite no significant change in adiposity. Overall, inhibition of 
long chain fatty acid B-oxidation in skeletal muscle of AY mice has proven to embody a mouse 
model in a metabolically healthy, yet obese state. Further investigation is needed in order to 
unveil the mechanisms driving the improvements in metabolic health that are observed when 
Cpt1b is inhibited in skeletal muscle. 
 
 
 
 
 
 
 
 
 
  
34 
 
Works Cited 
 
Badin, P. M., Louche, K., Mairal, A., Liebisch, G., Schmitz, G., Rustan, A. C., . . . Moro, C. 
(2011). Altered skeletal muscle lipase expression and activity contribute to insulin 
resistance in humans. Diabetes, 60(6), 1734-1742. doi:10.2337/db10-1364 
Bruce, C. R., Hoy, A. J., Turner, N., Watt, M. J., Allen, T. L., Carpenter, K., . . . Kraegen, E. W. 
(2009). Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient 
to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. 
Diabetes, 58(3), 550-558. doi:10.2337/db08-1078 
Cobb, J., & Dukes, I. (1998). Chapter 21 - Recent Advances in the Development of Agents for 
the Treatment of Type 2 Diabetes. In J. A. Bristol (Ed.), Annual Reports in Medicinal 
Chemistry (Vol. 33, pp. 213-222): Academic Press. 
Day, E. A., Ford, R. J., Smith, B. K., Mohammadi-Shemirani, P., Morrow, M. R., Gutgesell, R. 
M., . . . Steinberg, G. R. (2019). Metformin-induced increases in GDF15 are important 
for suppressing appetite and promoting weight loss. Nature Metabolism, 1(12), 1202-
1208. doi:10.1038/s42255-019-0146-4 
Dutia, R., Kim, A. J., Modes, M., Rothlein, R., Shen, J. M., Tian, Y. E., . . . Wardlaw, S. L. 
(2013). Effects of AgRP inhibition on energy balance and metabolism in rodent models. 
PloS one, 8(6), e65317-e65317. doi:10.1371/journal.pone.0065317 
Finck, B. N., Bernal-Mizrachi, C., Han, D. H., Coleman, T., Sambandam, N., LaRiviere, L. L., . . 
. Kelly, D. P. (2005). A potential link between muscle peroxisome proliferator- activated 
receptor-alpha signaling and obesity-related diabetes. Cell Metab, 1(2), 133-144. 
doi:10.1016/j.cmet.2005.01.006 
Fisher, F. M., & Maratos-Flier, E. (2016). Understanding the Physiology of FGF21. Annu Rev 
Physiol, 78, 223-241. doi:10.1146/annurev-physiol-021115-105339 
Hardy, O. T., Czech, M. P., & Corvera, S. (2012). What causes the insulin resistance underlying 
obesity? Curr Opin Endocrinol Diabetes Obes, 19(2), 81-87. 
doi:10.1097/MED.0b013e3283514e13 
Hsu, J. Y., Crawley, S., Chen, M., Ayupova, D. A., Lindhout, D. A., Higbee, J., . . . Allan, B. B. 
(2017). Non-homeostatic body weight regulation through a brainstem-restricted receptor 
for GDF15. Nature, 550(7675), 255-259. doi:10.1038/nature24042 
Iwatsuka, H., Shino, A., & Suzuoki, Z. (1970). General Survey of Diabetic Features of Yellow 
KK Mice. Endocrinologia Japonica, 17(1), 23-35. doi:10.1507/endocrj1954.17.23 
Kelly, R., Alonso, S., Tajbakhsh, S., Cossu, G., & Buckingham, M. (1995). Myosin Light Chain 
3F Regulatory Sequences Confer Regionalized Cardiac and Skeletal Muscle Expression 
in Transgenic Mice. The Journal of Cell Biology, 129(2), 383-396.  
35 
 
Keung, W., Ussher, J. R., Jaswal, J. S., Raubenheimer, M., Lam, V. H., Wagg, C. S., & 
Lopaschuk, G. D. (2013). Inhibition of carnitine palmitoyltransferase-1 activity alleviates 
insulin resistance in diet-induced obese mice. Diabetes, 62(3), 711-720. 
doi:10.2337/db12-0259 
Kim, T., He, L., Johnson, M. S., Li, Y., Zeng, L., Ding, Y., . . . Yang, Q. (2014). Carnitine 
Palmitoyltransferase 1b Deficiency Protects Mice from Diet-Induced Insulin Resistance. 
J Diabetes Metab, 5(4), 361. doi:10.4172/2155-6156.1000361 
Kim, T., Moore, J. F., Sharer, J. D., Yang, K., Wood, P. A., & Yang, Q. (2014). Carnitine 
Palmitoyltransferase 1b Deficient Mice Develop Severe Insulin Resistance After 
Prolonged High Fat Diet Feeding. J Diabetes Metab, 5. doi:10.4172/2155-6156.1000401 
Knowler, W. C. B.-C., E.; Fowler, S. E.; Hamman, R. F.; Lachin, J. M.; Walker, E. A.; Nathan, 
D. M. (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or 
metformin. New England Journal of Medicine, 346(6), 393-403.  
Koegler, F. H., Schafffhauser, A. O., Mynatt, R. L., York, D. A., & Bary, G. A. (1999). 
Macronutrient Diet Intake of the Lethal Yellow Agouti (A y/a) Mouse. Physiology & 
Behavior, 67, 809-812.  
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., . . . Muoio, D. 
M. (2008). Mitochondrial overload and incomplete fatty acid oxidation contribute to 
skeletal muscle insulin resistance. Cell Metab, 7(1), 45-56. 
doi:10.1016/j.cmet.2007.10.013 
Laboratory, J. (2006). The Cre-lox and FLP-FRT systems. JAX NOTES.  
Lee, J., Choi, J., Selen Alpergin, E. S., Zhao, L., Hartung, T., Scafidi, S., . . . Wolfgang, M. J. 
(2017). Loss of Hepatic Mitochondrial Long-Chain Fatty Acid Oxidation Confers 
Resistance to Diet-Induced Obesity and Glucose Intolerance. Cell Rep, 20(3), 655-667. 
doi:10.1016/j.celrep.2017.06.080 
Li, D., Zhang, H., & Zhong, Y. (2018). Hepatic GDF15 is regulated by CHOP of the unfolded 
protein response and alleviates NAFLD progression in obese mice. Biochem Biophys Res 
Commun, 498(3), 388-394. doi:10.1016/j.bbrc.2017.08.096 
Luan, H. H., Wang, A., Hilliard, B. K., Carvalho, F., Rosen, C. E., Ahasic, A. M., . . . 
Medzhitov, R. (2019). GDF15 Is an Inflammation-Induced Central Mediator of Tissue 
Tolerance. Cell, 178(5), 1231-1244 e1211. doi:10.1016/j.cell.2019.07.033 
Michaud, E. J., Bultman, S. J., Klebig, M. L., van Vugt, M. J., Stubbs, L. J., Russell, L. B., & 
Woychik, R. P. (1994). A molecular model for the genetic and phenotypic characteristics 
of the mouse lethal yellow (Ay) mutation. Proceedings of the National Academy of 
Sciences, 91(7), 2562-2566. doi:10.1073/pnas.91.7.2562 
36 
 
Miltenberger, R. J., Mynatt, R. L., Wilkinson, J. E., & Woychik, R. P. (1997). The Role of the 
agouti Gene in the Yellow Obese Syndrome. The Journal of Nutrition, 127(9), 1902S-
1907S. doi:10.1093/jn/127.9.1902S 
Nachman, M. W., Hoekstra, H. E., & D'Agostino, S. L. (2003). The genetic basis of adaptive 
melanism in pocket mice. Proceedings of the National Academy of Sciences, 100(9), 
5268-5273. doi:10.1073/pnas.0431157100 
O'Neill, H. M. (2013). AMPK and Exercise: Glucose Uptake and Insulin Sensitivity. Diabetes 
Metab J, 37(1), 1-21. doi:10.4093/dmj.2013.37.1.1 
Ollmann, M. M., Lamoreux, M. L., Wilson, B. D., & Barsh, G. S.  . (1998). Interaction of Agouti 
protein with the melanocortin 1 receptor in vitro and in vivo. Genes & development, 
12(3), 316-330.  
Pagel-Langenickel, I., Bao, J., Pang, L., & Sack, M. N. (2010). The role of mitochondria in the 
pathophysiology of skeletal muscle insulin resistance. Endocr Rev, 31(1), 25-51. 
doi:10.1210/er.2009-0003 
Perdomo, G., Commerford, S. R., Richard, A. M., Adams, S. H., Corkey, B. E., O'Doherty, R. 
M., & Brown, N. F. (2004). Increased beta-oxidation in muscle cells enhances insulin-
stimulated glucose metabolism and protects against fatty acid-induced insulin resistance 
despite intramyocellular lipid accumulation. J Biol Chem, 279(26), 27177-27186. 
doi:10.1074/jbc.M403566200 
Rufer, A. C., Thoma, R., & Hennig, M. (2009). Structural insight into function and regulation of 
carnitine palmitoyltransferase. Cellular and Molecular Life Sciences, 66(15), 2489-2501. 
doi:10.1007/s00018-009-0035-1 
Sebastian, D., Herrero, L., Serra, D., Asins, G., & Hegardt, F. G. (2007). CPT I overexpression 
protects L6E9 muscle cells from fatty acid-induced insulin resistance. Am J Physiol 
Endocrinol Metab, 292(3), E677-686. doi:10.1152/ajpendo.00360.2006 
Tao, Y.-X. (2010). The melanocortin-4 receptor: physiology, pharmacology, and 
pathophysiology. Endocrine reviews, 31(4), 506-543. doi:10.1210/er.2009-0037 
Vandanmagsar, B., Warfel, J. D., Wicks, S. E., Ghosh, S., Salbaum, J. M., Burk, D., . . . Mynatt, 
R. L. (2016). Impaired Mitochondrial Fat Oxidation Induces FGF21 in Muscle. Cell Rep, 
15(8), 1686-1699. doi:10.1016/j.celrep.2016.04.057 
Wang, O., & Majzoub, J. A. (2011). Chapter 3 - Adrenocorticotropin. In S. Melmed (Ed.), The 
Pituitary (Third Edition) (pp. 47-81). San Diego: Academic Press. 
Warfel, J. D., Bermudez, E. M., Mendoza, T. M., Ghosh, S., Zhang, J., Elks, C. M., . . . 
Vandanmagsar, B. (2016). Mitochondrial fat oxidation is essential for lipid-induced 
inflammation in skeletal muscle in mice. Sci Rep, 6, 37941. doi:10.1038/srep37941 
37 
 
Warfel, J. D., Vandanmagsar, B., Wicks, S. E., Zhang, J., Noland, R. C., & Mynatt, R. L. (2017). 
A low fat diet ameliorates pathology but retains beneficial effects associated with CPT1b 
knockout in skeletal muscle. PloS one, 12(12), e0188850. 
doi:10.1371/journal.pone.0188850 
Wicks, S. E., Vandanmagsar, B., Haynie, K. R., Fuller, S. E., Warfel, J. D., Stephens, J. M., . . . 
Mynatt, R. L. (2015). Impaired mitochondrial fat oxidation induces adaptive remodeling 
of muscle metabolism. Proc Natl Acad Sci U S A, 112(25), E3300-3309. 
doi:10.1073/pnas.1418560112 
Wicks, S. E., Vandanmagsar, B., Haynie, K. R., Fuller, S. E., Warfel, J. D., Stephens, J. M., . . . 
Mynatt, R. L. (2015). Impaired mitochondrial fat oxidation induces adaptive remodeling 
of muscle metabolism. Proceedings of the National Academy of Sciences, 112(25), 
E3300-E3309. doi:10.1073/pnas.1418560112 
Wilson-Fritch, L., Nicoloro, S., Chouinard, M., Lazar, M. A., Chui, P. C., Leszyk, J., . . . 
Corvera, S. (2004). Mitochondrial remodeling in adipose tissue associated with obesity 
and treatment with rosiglitazone. J Clin Invest, 114(9), 1281-1289. doi:10.1172/JCI21752 
 
 
  
38 
 
Vita 
 
Allison Stone, received her bachelor’s degree from Southeastern Louisiana University in 2017. 
She decided to go back to school to pursue a master’s degree in 2018. As her interest in health 
and wellness grew, she decided to enter the Department of Nutrition and Food Sciences at 
Louisiana State University. Upon completion of her master’s degree, she plans to continue to 
expand her knowledge in the field of health and wellness. 
 
